Login to Your Account

Karyopharm sinks on AML sepsis rates, says other trials not affected

By Jennifer Boggs
Managing Editor

Monday, August 10, 2015
Shares of Karyopharm Therapeutics Inc. hit a new 52-week low Monday on news that a higher-than-expected rate of sepsis prompted the firm to reduce the dose in an ongoing phase IIb study testing selinexor in elderly patients with AML.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription